Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.09%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.46%XMRUSDT+7.09%DOGEUSD+72.43%LINKUSD+1.03%XLMUSD+1.76%BCHUSDT+2.47%LTCUSD+64.72%UNIUSD+5.25%TONUSD+74.91%SUIUSD-0.68%HBARUSDT+0.39%TAOUSDT+2.40%AAVEUSD-0.71%ONDOUSDT-0.62%DOTUSDT-1.60%ICPUSDT-5.80%WLDUSDT-0.52%ARBUSDT-0.96%ATOMUSDT-3.84%INJUSDT-4.57%STXUSDT+2.91%PYTHUSDT+0.33%TIAUSDT-1.31%FETUSDT-3.07%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.60%OPUSDT+0.63%IOTAUSDT-1.77%POLUSDT-0.09%WIFUSDT-2.78%AXSUSDT+0.59%EOSUSDT+0.85%IMXUSDT-3.33%FARTCOINUSDT-0.20%GALAUSDT-2.18%DYDXUSDT-3.52%ORDIUSDT-0.27%NOTUSDT-1.52%RONINUSDT+0.62%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.09%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.46%XMRUSDT+7.09%DOGEUSD+72.43%LINKUSD+1.03%XLMUSD+1.76%BCHUSDT+2.47%LTCUSD+64.72%UNIUSD+5.25%TONUSD+74.91%SUIUSD-0.68%HBARUSDT+0.39%TAOUSDT+2.40%AAVEUSD-0.71%ONDOUSDT-0.62%DOTUSDT-1.60%ICPUSDT-5.80%WLDUSDT-0.52%ARBUSDT-0.96%ATOMUSDT-3.84%INJUSDT-4.57%STXUSDT+2.91%PYTHUSDT+0.33%TIAUSDT-1.31%FETUSDT-3.07%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.60%OPUSDT+0.63%IOTAUSDT-1.77%POLUSDT-0.09%WIFUSDT-2.78%AXSUSDT+0.59%EOSUSDT+0.85%IMXUSDT-3.33%FARTCOINUSDT-0.20%GALAUSDT-2.18%DYDXUSDT-3.52%ORDIUSDT-0.27%NOTUSDT-1.52%RONINUSDT+0.62%

Thermo Fisher debuts VaxEvo CD 293 medium

NEWS

November 18, 2026 at 14:06 UTC

3 min read
Stainless steel bioreactor in a vaccine production suite illustrating new HEK293 adenovirus medium launch

Key Points

  • 01Thermo Fisher launches Gibco VaxEvo CD 293 Medium for adenovirus vaccines
  • 02New medium is chemically defined and animal origin-free for HEK293 cells
  • 03Product targets human and animal health vaccine developers using suspension HEK293
  • 04Benchmarking shows adenovirus titers up to 5.7-fold higher in some comparisons

Thermo Fisher unveils VaxEvo CD 293 for adenovirus vaccines

Thermo Fisher Scientific has introduced Gibco VaxEvo CD 293 Medium, a new cell culture medium designed to advance adenovirus vaccine production. The chemically defined, animal origin-free medium is intended to support suspension HEK293 cell growth and high-titer adenovirus production, providing a purpose-built option for vaccine developers working with adenoviral vectors. The launch focuses on enabling workflows that span from early process development through scale-up and manufacturing.

The VaxEvo CD 293 Medium is categorized as a chemically defined cell culture medium for suspension HEK293 cells. It is formulated to combine robust HEK293 cell growth with strong adenovirus productivity while simplifying upstream workflows. By aligning productivity with process simplicity and manufacturing readiness, the product seeks to address evolving needs in adenovirus-based vaccine processes.

Product features and formulation

VaxEvo CD 293 Medium is described as chemically defined and animal origin-free, which is important for consistent performance and regulatory acceptance in vaccine manufacturing. The medium is designed for use in suspension-based HEK293 workflows, supporting scalable adenoviral vector and adenovirus vaccine production. It is available in both liquid and AGT formats, with multiple AGT package sizes to fit different process scales.

The medium supports suspension HEK293 cell growth while enabling high-titer adenovirus production. It is intended for adenovirus production, vaccine process development, scale-up, and manufacturing applications. The platform aims to provide a single medium that can be used from early development through manufacturing, helping streamline workflow transitions as processes move toward larger scales.

Target users and applications

Thermo Fisher is targeting human and animal health vaccine developers and manufacturers using suspension HEK293 cells as primary users of VaxEvo CD 293 Medium. The product is designed for vaccine process development scientists and upstream manufacturing teams focused on adenovirus-based applications. These include adenoviral vectors for vaccines, adenovirus vaccine production, and oncolytic virus production using HEK293 suspension cultures.

As suspension-based HEK293 workflows evolve to support scalable adenovirus vaccine production, developers are seeking media that can deliver strong productivity while reducing process complexity. VaxEvo CD 293 Medium is positioned to help these users evaluate a purpose-designed medium that supports productivity, process simplicity, and manufacturing readiness within a single platform.

Benchmarking performance and workflow impact

In laboratory benchmarking studies using HEK293 cells, VaxEvo CD 293 Medium supported average adenovirus type 5 titers that were comparable to select supplier media. In some comparisons, titers reached up to 5.7-fold higher levels. These studies also showed that the medium achieved comparable or higher adenovirus titers without a dedicated feed, compared with select benchmark media used with their recommended feeds.

By combining adenovirus productivity, robust HEK293 cell growth, and process simplicity, VaxEvo CD 293 Medium is intended to help vaccine developers progress from process development toward manufacturing with fewer process changes. The emphasis on manufacturing readiness highlights how early media choices can shape process performance, complexity, and the path to scale in adenovirus-based vaccine production.

Key Takeaways

  • 01Thermo Fisher’s VaxEvo CD 293 Medium targets the full adenovirus vaccine workflow, from early development to manufacturing, in a single chemically defined platform.
  • 02The medium is designed to simplify suspension HEK293 processes by delivering robust cell growth and high adenovirus titers without requiring a dedicated feed in benchmarking studies.
  • 03Benchmark data showing adenovirus type 5 titers up to 5.7-fold higher in some comparisons underscores the product’s focus on both productivity and process efficiency.

Thermo Fisher debuts VaxEvo CD 293 medium | Trading Dashboard